+2 year(s) experience
As an Analyst, she combines secondary research with interviews from payers and payer-advising key opinion leaders to give her perspective on the commercial and clinical attractiveness of current and pipeline products.
She has produced pricing and reimbursement reports on asthma, COPD, psoriasis, and psoriatic arthritis, and also covers other indications in immunology and inflammation, respiratory system, and multiple sclerosis.
Astrid Writes For
By Astrid Kurniawan 25 Aug 2015
Gilead is negotiating Sovaldi’s (sofosbuvir) pricing with the Chinese government. This is a necessary step to ensure the company captures China’s large hepatitis C population, following its decision to exclude the country from its drug access program, and to also avoid the potential negative repercussions in other emerging markets should China resort to compulsory licensing.
Topics Drug approval
11 Jul 2016